Castle Biosciences Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Castle Biosciences Inc 公司

Castle Biosciences, Inc. 是一家商业阶段诊断公司。该公司专注于为医生及其患者提供个性化、临床可操作的信息，以便医生及其患者做出治疗决策并改善健康结果。其产品组合包括皮肤癌、葡萄膜黑色素瘤、巴雷特食管和精神健康状况的检测。其产品包括 DecisionDx-Melanoma、DecisionDx-SCC、MyPath Melanoma、TissueCypher 和 DecisionDx-UM、IDgenetix。DecisionDx-Melanoma 是一种风险分层基因表达谱 (GEP) 测试，可预测被诊断为侵袭性皮肤黑色素瘤 (CM)（一种致命皮肤癌）的患者的转移或复发风险。MyPath Melanoma 是针对难以诊断的黑色素细胞病变患者的 GEP 测试。 IDgenetix 是一种药物基因组学 (PGx) 测试，有助于指导患有重度抑郁症、躁郁症等的患者进行最佳药物治疗。

公司简介

公司代码CSTL

公司名称Castle Biosciences Inc

上市日期Jul 25, 2019

CEOMr. Derek J. Maetzold

员工数量761

证券类型Ordinary Share

年结日Jul 25

公司地址505 S Friendswood Drive

城市FRIENDSWOOD

上市交易所NASDAQ Global Market Consolidated

国家United States of America

邮编77546

电话18667889007

网址https://castlebiosciences.com/

公司代码CSTL

上市日期Jul 25, 2019

CEOMr. Derek J. Maetzold

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Derek J. Maetzold

President, Chief Executive Officer, Founder, Director

359.23K

-0.37%

Ms. Kristen M. Oelschlager

Chief Operating Officer

141.12K

-13.93%

Mr. Tobin W. (Toby) Juvenal

Chief Commercial Officer

86.76K

+7.89%

Mr. Frank Stokes

Chief Financial Officer

48.72K

+12.44%

Ms. Ellen Goldberg

Independent Director

27.25K

+46.68%

Mr. Miles D. Harrison

Independent Director

21.96K

+65.25%

Mr. Rodney Cotton

Independent Director

19.33K

+81.38%

Ms. Tiffany P. Olson

Independent Director

--

Ms. Kimberlee S. Caple

Independent Director

--

Mr. Daniel Mark (Dan) Bradbury

Independent Chairman of the Board

--

名称

名称/职务

职务

持股

持股变动

Mr. Derek J. Maetzold

President, Chief Executive Officer, Founder, Director

359.23K

-0.37%

Ms. Kristen M. Oelschlager

Chief Operating Officer

141.12K

-13.93%

Mr. Tobin W. (Toby) Juvenal

Chief Commercial Officer

86.76K

+7.89%

Mr. Frank Stokes

Chief Financial Officer

48.72K

+12.44%

Ms. Ellen Goldberg

Independent Director

27.25K

+46.68%

Mr. Miles D. Harrison

Independent Director

21.96K

+65.25%

收入明细

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

暂无数据

地区USD

名称

营收

占比

United States

87.99M

0.00%

业务

地区

暂无数据

股东统计

更新时间: 8月17日周日

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

8.20%

The Vanguard Group, Inc.

7.43%

Principal Global Investors (Equity)

6.20%

Portolan Capital Management, L.L.C.

5.13%

Dimensional Fund Advisors, L.P.

4.75%

其他

68.28%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

8.20%

The Vanguard Group, Inc.

7.43%

Principal Global Investors (Equity)

6.20%

Portolan Capital Management, L.L.C.

5.13%

Dimensional Fund Advisors, L.P.

4.75%

其他

68.28%

股东类型

持股股东

占比

Investment Advisor

39.03%

Investment Advisor/Hedge Fund

34.23%

Hedge Fund

15.08%

Research Firm

2.99%

Individual Investor

2.85%

Pension Fund

1.10%

Bank and Trust

0.50%

Venture Capital

0.16%

Corporation

0.05%

其他

4.01%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

404

27.92M

96.24%

-3.18M

2025Q1

423

27.42M

95.08%

-3.59M

2024Q4

413

27.81M

97.60%

-2.39M

2024Q3

414

27.79M

100.23%

-3.05M

2024Q2

400

27.44M

99.43%

-4.42M

2024Q1

407

28.20M

102.27%

-5.76M

2023Q4

407

26.80M

99.62%

-6.63M

2023Q3

416

26.10M

97.38%

-6.68M

2023Q2

414

24.88M

93.24%

-6.39M

2023Q1

420

24.03M

90.08%

-9.68M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

2.31M

8.01%

+53.08K

+2.35%

Mar 31, 2025

The Vanguard Group, Inc.

2.04M

7.07%

+215.03K

+11.77%

Mar 31, 2025

Principal Global Investors (Equity)

1.47M

5.08%

+32.21K

+2.24%

Mar 31, 2025

Portolan Capital Management, L.L.C.

1.61M

5.58%

+345.88K

+27.34%

Apr 07, 2025

Dimensional Fund Advisors, L.P.

1.20M

4.16%

+200.76K

+20.09%

Mar 31, 2025

Wasatch Global Investors Inc

998.46K

3.46%

-797.63K

-44.41%

Mar 31, 2025

Braidwell LP

365.25K

1.26%

+365.25K

--

Mar 31, 2025

Nuveen LLC

723.60K

2.51%

+369.89K

+104.57%

Mar 31, 2025

State Street Global Advisors (US)

715.03K

2.48%

+4.82K

+0.68%

Mar 31, 2025

持股ETF

更新时间: 9月6日周六

机构名称

占比

SPDR S&P Health Care Services ETF

1.42%

Inspire Small/Mid Cap ESG ETF

0.23%

iShares U.S. Healthcare Providers ETF

0.15%

iShares Micro-Cap ETF

0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.08%

iShares Biotechnology ETF

0.06%

iShares ESG Aware MSCI USA Small-Cap ETF

0.06%

Nuveen ESG Small-Cap ETF

0.06%

Avantis US Small Cap Equity ETF

0.05%

iShares Russell 2000 Value ETF

0.05%

SPDR S&P Health Care Services ETF

占比1.42%

Inspire Small/Mid Cap ESG ETF

占比0.23%

iShares U.S. Healthcare Providers ETF

占比0.15%

iShares Micro-Cap ETF

占比0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0.08%

iShares Biotechnology ETF

占比0.06%

iShares ESG Aware MSCI USA Small-Cap ETF

占比0.06%

Nuveen ESG Small-Cap ETF

占比0.06%

Avantis US Small Cap Equity ETF

占比0.05%

iShares Russell 2000 Value ETF

占比0.05%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Castle Biosciences Inc

23.460USD

Castle Biosciences Inc

23.460

概览

公司

财务

分析